Get started
Author

Janani Ravikrishnan

Shear contributions to cell culture performance and product recovery in ATF and TFF perfusion systems
2017 · Samantha Wang, Scott Godfrey, et al. · Journal of Biotechnology · 126
PDF
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
2022 · Steven Sher, Ethan Whipp, et al. · Leukemia · 39
PDF
Manipulation of the sodium‐potassium ratio as a lever for controlling cell growth and improving cell specific productivity in perfusion CHO cell cultures
2017 · Samantha B. Wang, Alexandria Lee‐Goldman, et al. · Biotechnology and Bioengineering · 22
HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia
2022 · Tzung-Huei Lai, Hatice Gulcin Ozer, et al. · Blood Advances · 17
PDF
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
2022 · Elizabeth M. Muhowski, Janani Ravikrishnan, et al. · Journal of Hematology & Oncology · 15
PDF
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia
2024 · Janani Ravikrishnan, Daisy Y. Diaz-Rohena, et al. · Haematologica · 14
Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy
2022 · Max Yano, Chia Sharpe, et al. · Blood Advances · 13
Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax
2021 · Janani Ravikrishnan, Elizabeth M. Muhowski, et al. · Blood · 10
Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168
2023 · Britten Gordon, Elizabeth Muhowski, et al. · Blood · 8
Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader
2022 · Daisy Diaz Rohena, Bailey Slawin, et al. · Blood · 5
Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation
2021 · Daisy Diaz Rohena, Janani Ravikrishnan, et al. · Blood · 4
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics
2019 · Tzung-Huei Lai, Shaneice Mitchell, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2025 · Britten K. Gordon, Elizabeth M. Muhowski, et al. · Blood Cancer Discovery · 3
P1269: Vip152 Is a Novel Cdk9 Inhibitor With Improved Selectivity, Target Modulation, and Cardiac Safety in Patients With Lymphoma
2022 · M. Frigault, S. Sher, et al. · HemaSphere · 3
The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia
2019 · Elizabeth M. Muhowski, Amy M. Lehman, et al. · Blood · 2
Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia
2019 · Janani Ravikrishnan, Tzung-Huei Lai, et al. · Blood · 2
The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia
2023 · Britten Gordon, Elizabeth Muhowski, et al. · Blood · 1
PDF
Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader
2023 · Daisy Diaz Rohena, Arnau Peris Cuesta, et al. · Blood · 1
MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL
2022 · Jyotsana Singh, Daisy Diaz Rohena, et al. · Blood · 1
PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds
2022 · Claire Hinterschied, Fiona Brown, et al. · Blood · 1
Development of highly intensified cell culture perfusion media and process with tremendous productivity potential, while having a low cell bleed requirement for maintaining an overall high yield
2017 · Henry Lin, Samantha Wang, et al. · 1
Supplementary Figure S8 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · Britten K. Gordon, Elizabeth M. Muhowski, et al.
PDF
Supplementary Figure S7 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · Britten K. Gordon, Elizabeth M. Muhowski, et al.
PDF
Supplementary Figure S10 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · Britten K. Gordon, Elizabeth M. Muhowski, et al.
PDF
Supplementary Table S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · Britten K. Gordon, Elizabeth M. Muhowski, et al.
Works count: 46
Citation count: 292
H-index: 8
I10-index: 8
Year
Topic
Type